Cargando…

Comparative Analysis of Enzyme and Pathway Engineering Strategies for 5FC-Mediated Suicide Gene Therapy Applications

Bacterial and yeast encoded cytosine deaminases (bCD and yCD, respectively) are widely investigated suicide enzymes used in combination with the prodrug 5-fluorocytosine (5FC) to achieve localized cytotoxicity. Yet characteristics such as poor turnover rates of 5FC (bCD) and enzyme thermolability (y...

Descripción completa

Detalles Bibliográficos
Autores principales:	Johnson, Adam J., Ardiani, Andressa, Sanchez-Bonilla, Marilyn, Black, Margaret E.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	2011
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3139007/ https://www.ncbi.nlm.nih.gov/pubmed/21394105 http://dx.doi.org/10.1038/cgt.2011.6

Ejemplares similares

Fusion Enzymes Containing HSV-1 Thymidine Kinase Mutants and Guanylate Kinase Enhance Prodrug Sensitivity In Vitro and In Vivo
por: Ardiani, Andressa, et al.
Publicado: (2009)

Novel asymmetrically engineered antibody Fc variant with superior FcγR binding affinity and specificity compared with afucosylated Fc variant
por: Mimoto, Futa, et al.
Publicado: (2013)

The influence of antibody engineering on Fc conformation and Fc receptor binding properties: Analysis of FcRn-binding engineered antibodies and an Fc fusion protein
por: Suzuki, Takuo, et al.
Publicado: (2021)

Fc Engineering Strategies to Advance IgA Antibodies as Therapeutic Agents
por: van Tetering, Geert, et al.
Publicado: (2020)

Androgen deprivation therapy increases the sensitivity of human prostate carcinoma cells to T cell-mediated lysis through an androgen receptor dependent mechanism
por: Gameiro, Sofia, et al.
Publicado: (2014)

Effects of Cabozantinib, a small molecule tyrosine kinase inhibitor, on the immune permissiveness of the tumor microenvironment and immune-mediated killing of tumor cells
por: Kwilas, Anna R, et al.
Publicado: (2014)

Rational engineering of Fc/Fc receptor interactions to improve antibody potency
por: Doberstein, S, et al.
Publicado: (2003)

Androgen deprivation therapy sensitizes prostate cancer cells to T-cell killing through androgen receptor dependent modulation of the apoptotic pathway
por: Ardiani, Andressa, et al.
Publicado: (2014)

Enhancing CDC and ADCC of CD19 Antibodies by Combining Fc Protein-Engineering with Fc Glyco-Engineering
por: Roßkopf, Sophia, et al.
Publicado: (2020)

Dual effects of a targeted small-molecule inhibitor (cabozantinib) on immune-mediated killing of tumor cells and immune tumor microenvironment permissiveness when combined with a cancer vaccine
por: Kwilas, Anna R, et al.
Publicado: (2014)

Fc-Engineered Antibodies with Enhanced Fc-Effector Function for the Treatment of B-Cell Malignancies
por: van der Horst, Hilma J., et al.
Publicado: (2020)

Attacking malignant cells that survive therapy: Exploiting immunogenic modulation
por: Hodge, James W, et al.
Publicado: (2013)

Radiation-induced survival responses promote immunogenic modulation to enhance immunotherapy in combinatorial regimens
por: Gameiro, Sofia R, et al.
Publicado: (2014)

Androgen deprivation therapy sensitizes triple negative breast cancer cells to immune-mediated lysis through androgen receptor independent modulation of osteoprotegerin
por: Kwilas, Anna R., et al.
Publicado: (2016)

Engineering of Immunoglobulin Fc Heterodimers Using Yeast Surface-Displayed Combinatorial Fc Library Screening
por: Choi, Hye-Ji, et al.
Publicado: (2015)

Antibody Fc engineering for enhanced neonatal Fc receptor binding and prolonged circulation half-life
por: Mackness, Brian C., et al.
Publicado: (2019)

Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
por: Wines, Bruce D., et al.
Publicado: (2022)

Engineered antibody Fc variant with selectively enhanced FcγRIIb binding over both FcγRIIa(R131) and FcγRIIa(H131)
por: Mimoto, F., et al.
Publicado: (2013)

Fc Receptor-Mediated Phagocytosis in Tissues as a Potent Mechanism for Preventive and Therapeutic HIV Vaccine Strategies
por: Sips, Magdalena, et al.
Publicado: (2016)

Engineering of Fc Fragments with Optimized Physicochemical Properties Implying Improvement of Clinical Potentials for Fc-Based Therapeutics
por: Yang, Chunpeng, et al.
Publicado: (2018)

Corrigendum: Fc engineered ACE2-Fc is a potent multifunctional agent targeting SARS-CoV2
por: Wines, Bruce D., et al.
Publicado: (2023)

Chemoenzymatic Fc Glycosylation via Engineered Aldehyde Tags
por: Smith, Elizabeth L., et al.
Publicado: (2014)

Editorial: Antibody Fc Engineering: Towards Better Therapeutics
por: Lei, Cheng, et al.
Publicado: (2018)

Engineered IgG1-Fc Molecules Define Valency Control of Cell Surface Fcγ Receptor Inhibition and Activation in Endosomes
por: Bailey, Elizabeth M., et al.
Publicado: (2021)

An Engineered Human Fc variant With Exquisite Selectivity for FcγRIIIa(V158) Reveals That Ligation of FcγRIIIa Mediates Potent Antibody Dependent Cellular Phagocytosis With GM-CSF-Differentiated Macrophages
por: Kang, Tae Hyun, et al.
Publicado: (2019)

Engineering of Metabolic Pathways by Artificial Enzyme Channels
por: Pröschel, Marlene, et al.
Publicado: (2015)

Engineered hexavalent Fc proteins with enhanced Fc-gamma receptor avidity provide insights into immune-complex interactions
por: Rowley, Tania F., et al.
Publicado: (2018)

The Fc receptor on thymus-derived lymphocytes. III. Mixed lymphocyte reactivity and cell-mediated lympholytic activity of Fc- and Fc+ T lymphocytes
Publicado: (1976)

The role of Fc–FcγR interactions in IgG-mediated microbial neutralization
por: Bournazos, Stylianos, et al.
Publicado: (2015)

Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities
por: Chen, Yaozong, et al.
Publicado: (2021)

Engineered ACE2-Fc counters murine lethal SARS-CoV-2 infection through direct neutralization and Fc-effector activities
por: Chen, Yaozong, et al.
Publicado: (2022)

B Cell-Based Seamless Engineering of Antibody Fc Domains
por: Hashimoto, Koji, et al.
Publicado: (2016)

Fc Engineering for Developing Therapeutic Bispecific Antibodies and Novel Scaffolds
por: Liu, Hongyan, et al.
Publicado: (2017)

IgG Fc engineering to modulate antibody effector functions
por: Wang, Xinhua, et al.
Publicado: (2017)

Asymmetric Fc Engineering for Bispecific Antibodies with Reduced Effector Function
por: Escobar-Cabrera, Eric, et al.
Publicado: (2017)

Engineered Fc-glycosylation switch to eliminate antibody effector function
por: Zhou, Qun, et al.
Publicado: (2020)

Engineering of Fc Multimers as a Protein Therapy for Autoimmune Disease
por: Fitzpatrick, Elizabeth A., et al.
Publicado: (2020)

Fc-engineered antibodies with immune effector functions completely abolished
por: Wilkinson, Ian, et al.
Publicado: (2021)

Fc-Engineered Therapeutic Antibodies: Recent Advances and Future Directions
por: Abdeldaim, Dalia T., et al.
Publicado: (2023)

Comparative Molecular Characterization and Pharmacokinetics of IgG1-Fc and Engineered Fc Human Antibody Variants to Insulin-like Growth Factor 2 Receptor (IGF2R)
por: Prabaharan, Chandra B., et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_nsult2f0qo53b5du331fmbqhg8